Discontinued Operations

3 Months Ended

Mar. 28, 2026

Discontinued Operations and Disposal Groups [Abstract]

Note 4: Discontinued Operations

As of December 27, 2025, the Company has characterized its Biotechnology segment as a discontinued operation on its financial statements, as follows: on May 21, 2025, the Company announced the planned formal separation of its healthcare assets, known as Alyea, and noted that the scope and method of a partial or full disposition, whatever the methodology, would be determined and announced at a later date.

In accordance with ASC 360-10 and ASC 205-20, the Company has separately reported the assets and liabilities of all of its discontinued operations in the consolidated balance sheets. These assets and liabilities have been reflected as discontinued operations as of March 28, 2026 and December 27, 2025, and consist of the following (in $000s):

Schedule Of Discontinued Operations

	March 28, 2026		December 27, 2025
Assets from discontinued operations
Other current assets		192		205
Total current assets from discontinued operations		192		205
Property and equipment, net ¹		1,170		1,170
Intangible assets, net ²		13,826		13,826
Deferred income taxes		776		776
Other assets		211		211
Total other assets from discontinued operations		15,983		15,983
Total assets from discontinued operations	$	16,174	$	16,188
Liabilities from discontinued operations
Accounts payable	$	79	$	54
Accrued liabilities - other ³		1,500		2,500
Total current liabilities from discontinued operations		1,579		2,554
Total noncurrent liabilities from discontinued operations		—		—
Total liabilities from discontinued operations	$	1,579	$	2,554

The Company’s property and equipment consisted of the following (in $000s):

	March 28, 2026		December 27, 2025
Buildings and improvements	$	—	$	—
Equipment		—		—
Projects under construction		1,170		1,170
Property and equipment		1,170		1,170
Property and equipment, gross		1,170		1,170
Less accumulated depreciation		—		—
Total property and equipment, net, from discontinued operations	$	1,170	$	1,170

No depreciation expense has been recorded for the 13 weeks ended March 28, 2026 and March 29, 2025, respectively.

The Company’s intangible assets consisted of the following:

	March 28, 2026			December 27, 2025
Soin intangible	$	19,293		$	19,293
Intangible assets		19,293			19,293
Less accumulated amortization		(5,467	)		(5,467	)
Total intangible assets	$	13,826		$	13,826

Amortization expense was $0.0 million for the 13 weeks ended March 28, 2026 and March 29, 2025, respectively.

Soin Intangible Assets

Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a 10-year period.

The Company’s accrued liabilities consisted of the following:

	March 28, 2026		December 27, 2025
Due to Dr. Soin	$	1,500	$	2,500
Other		—		—
Total accrued expenses	$	1,500	$	2,500

In accordance with the provisions of ASC 360-10 and ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for this entity for the 13 ended March 28, 2026 and March 27, 2025 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following:

	March 28, 2026			March 29, 2025
Revenues	$	—		$	—
Cost of revenues		—			—
Gross profit		—			—
Operating expenses from discontinued operations:
Selling, general and administrative expenses		177			540
Total operating expenses from discontinued operations		177			540
Operating loss from discontinued operations		(177	)		(540	)
Other income (expense) from discontinued operations
Total other expense, net		—			—
Loss before provision for income taxes from discontinued operations		(177	)		(540	)
Income tax provision benefit		-			60
Net loss from discontinued operations	$	(177	)	$	(480	)

In accordance with the provisions of ASC 360-10 and ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 13 weeks ended March 28, 2026 and March 27, 2025 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following:

	March 28, 2026			March 29, 2025
DISCONTINUED OPERATING ACTIVITIES:
Net (loss) income from discontinued operations		(177	)		(480	)
Depreciation and amortization		—			2,087
Noncash expense (benefit) funded by parent		1,138			(2,820	)
Accounts payable & accrued liabilities		(961	)		—
Net cash provided by operating activities from discontinued operations	$	—		$	(1,213	)
DISCONTINUED INVESTING ACTIVITIES:
Net cash used in investing activities from discontinued operations	$	—		$	—
DISCONTINUED FINANCING ACTIVITIES:
Net cash used in financing activities from discontinued operations	$	—		$	—
Effect of changes in exchange rate on cash and cash equivalents		—			—
DECREASE IN CASH AND CASH EQUIVALENTS		—			—
CASH AND CASH EQUIVALENTS, beginning of period		—			—
CASH AND CASH EQUIVALENTS, end of period	$	—		$	—